Global Down Syndrome

Summer 2018

Issue link: https://viewer.e-digitaledition.com/i/1038839

Contents of this Issue

Navigation

Page 8 of 31

gave her an important piece of advice: "If you do just one thing, create an academic home for Down syndrome research … and rebuild the pipeline of science." And so started Whitten's journey establishing the Global Down Syndrome Foundation and the Linda Crnic Institute for Down Syndrome, focused on research and medical care. "Following that meeting, we started traveling to Washington, D.C. almost every month to educate Congress and the NIH on this issue," says Whitten, President and CEO of Global. "We met so many families whose children had health issues, and they helped us with petitions, phone calls, letter writing, and face-to-face meetings. In our very first letter-writing campaign, 1,000 people contacted Congress advocating for more Down syndrome research funding. It wasn't easy, and it would take a decade to succeed, but we made it happen!" Fortunately, Global was able to attract scientists "brilliant of mind and heart" — Tom Blumenthal, Ph.D., Joaquín Espinosa, Ph.D., and Huntington Potter, Ph.D. Dr. Espinosa, now the Executive Director of the Crnic Institute, has clearly mapped out how people with Down syndrome have a different "disease spectrum" where they are highly predisposed or protected from major diseases that represent 60 percent of all the deaths in the U.S. Most importantly he made a game-changing discovery recasting Down syndrome as an immune system disorder. Armed with the support of the Down syndrome community and groundbreaking science, the pivotal point for Global came in fall 2017. On Wednesday, Oct. 25, 2017, for the first time in its history, the Appropriations Subcommittee on Labor, Health and Human Services, Education, and Related Agencies, which provides federal funding for the NIH, held a hearing on current and future research funding priorities for people with Down syndrome. The hearing included testimonies from Global and the Crnic Institute. Global had two goals: to move Down syndrome under a trans-NIH structure, since the condition touches so many diseases, and to reverse the terrible disparity of funding. The results were astounding, with the entire committee standing in ovation at the end of the hearing, primarily for the self-advocate testimony by Frank Stephens. The subsequent NIH funding increase was clearly led by Congressional champions: Chairs Rep. Cole and Sen. Blunt and Ranking Members Rep. DeLauro and Sen. Murray, as well as Reps. McMorris Rodgers, Sessions, Mike Coffman (R-CO), and Cheri Bustos (D-IL). At Global's inaugural AcceptAbility Gala in Washington, D.C. last May, Rep. Cole announced the historic and significant $23 million increase in Down syndrome research funding at the NIH from $35 million in fiscal year (FY) 2017 to $58 million in FY2018. A subsequent $98 million has been budgeted for FY2019. The NIH has embraced the FY2018 Omnibus Appropriations Report and has created a truly trans-NIH effort. Under the office of the Director, Down syndrome research will now be managed by the trans-NIH consortium "INCLUDE" (INvestigation of Co-occurring conditions across the Lifespan to Understand Down syndromE). Eighteen NIH institutes and centers comprise the consortium, and the steering committee is led by three great supporters of Down syndrome research: Lawrence Tabak, D.D.S., Ph.D., NIH Principal Deputy Director and INCLUDE Chair; Diana Bianchi, M.D., Director of the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD); and Gary Gibbons, M.D., Director of the National Heart, Lung, and Blood Institute. The FY2018 Omnibus Appropriations Report stated the following: "Down syndrome. The agreement directs the NIH Director to develop a new trans-NIH initiative — involving, at a minimum, NICHD, National Institute on Aging (NIA), and National Cancer Institute (NCI) — to study trisomy 21, with the aim of yielding scientific discoveries to improve the health and neurodevelopment of individuals with Down syndrome and typical individuals at risk for Alzheimer's disease, cancer, cardiovascular disease, immune system dysregulation, and autism, among others. This initiative shall bring together research results that will be available to academic researchers, nonprofit organizations, and industry researchers. Funding for this trans-NIH initiative will supplement, not supplant, existing NIH funding levels for Down syndrome research." Following are important excerpts from the official NIH "INCLUDE" project that highlight, in detail, how NIH intends to organize Down syndrome research under a trans-NIH banner and use $21 million of the $23 million increase in Down syndrome research funding. CONTINUED ON PAGE 10 THE 'INCLUDE' PROJECT RESEARCH PLAN In this project, NIH will not only expand its current efforts for Down syndrome and commonly co-occurring conditions in individuals with Down syndrome that are also seen in the general population, such as Alzheimer's disease/dementia, autism, cataracts, celiac disease, congenital heart disease, diabetes, and immune system dysregulation, but also build an integrated effort across NIH that will be truly transformative in these areas. Following collaborative discussions across its institutes and centers, NIH has identified three major components for INCLUDE, spanning basic to clinical research: 1. targeted high risk–high reward basic science studies 2. development of a cohort to perform deep phenotyping and study co-existing conditions 3. establishing a clinical trials network so therapies for co-occurring conditions can begin to be tested in the Down syndrome population as soon as possible, while also further supporting and expanding existing clinical trial infrastructure BACKGROUND INCLUDE will focus on Down syndrome, to improve the health and well-being of individuals with Down syndrome, and also to learn about risk and resilience factors for common diseases that they share with individuals who do not have Down syndrome. Down syndrome is associated with intellectual challenges, an increased prevalence of autism (10–18 percent) and epilepsy (1–13 percent), and Hirschsprung's disease. About 75 percent of individuals experience cognitive decline in a syndrome that resembles Alzheimer's disease but has its onset a decade or two earlier than typical Alzheimer's disease. Individuals with Down syndrome also have high rates of hearing loss (up to 75 percent), eye abnormalities (60 percent), congenital heart defects (about 50 percent), sleep apnea (50 percent), pulmonary hypertension GLOBALDOWNSYNDROME.ORG 9

Articles in this issue

Links on this page

Archives of this issue

view archives of Global Down Syndrome - Summer 2018